Title : Anti SARS Cov 2 Antibodies among Vaccinated Healthcare Workers Repeated Cross-sectional study in VIMSAR, Burla
Abstract:
Background – Since the day the Novel SARS Cov has been detected and the ensuing pandemic the search for a cure or prevention has been the only target of the medical fraternity. As the second wave racked havoc Vaccine seemed the only viable option to stop this global surge. WHO & subsequently Government of India have issued emergency use authorization to 2 vaccines. Our study is aimed at estimating the seroconversion rates and to identify predictors of antibody titres in vaccinated healthcare workers in VIMSAR, Burla.
Methods – This is a part of the ongoing repeated cross-sectional study. Participants were enrolled well above the Sample size (322) to increase precision. Two rounds of survey were conducted & is being reported. Serum IgG antibodies against spike protein of SARS-CoV-2 was estimated using Elecsys® Anti-SARS-CoV-2S is an immunoassay by ECLIA based Cobas e411 analyzer. Univariate and multivariate regression were used in statistical analysis.
Results - Our results show 95.1 % and 99.5% of the vaccinated individuals have developed anti spike protein antibodies after the 1st and 2nd dose respectively. Previous Covid infection was Significantly Correlated with antibody production and age was negatively correlated. No difference was reported for sex, occupation, diabetes.
Conclusion. Our interim analysis report is coherent with the available literature and research regarding high efficacy of Covid vaccine as far as seroconversion is concerned.
